These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16430786)

  • 1. BACH1 Ser919Pro variant and breast cancer risk.
    Vahteristo P; Yliannala K; Tamminen A; Eerola H; Blomqvist C; Nevanlinna H
    BMC Cancer; 2006 Jan; 6():19. PubMed ID: 16430786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families.
    Karppinen SM; Vuosku J; Heikkinen K; Allinen M; Winqvist R
    Eur J Cancer; 2003 Feb; 39(3):366-71. PubMed ID: 12565990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
    De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
    Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
    Dohrn L; Salles D; Siehler SY; Kaufmann J; Wiesmüller L
    Biochem J; 2012 Feb; 441(3):919-26. PubMed ID: 22032289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
    Cantor SB; Guillemette S
    Future Oncol; 2011 Feb; 7(2):253-61. PubMed ID: 21345144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase.
    Kumaraswamy E; Shiekhattar R
    Mol Cell Biol; 2007 Oct; 27(19):6733-41. PubMed ID: 17664283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
    Cantor S; Drapkin R; Zhang F; Lin Y; Han J; Pamidi S; Livingston DM
    Proc Natl Acad Sci U S A; 2004 Feb; 101(8):2357-62. PubMed ID: 14983014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
    Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
    Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
    Vahteristo P; Syrjäkoski K; Heikkinen T; Eerola H; Aittomäki K; von Smitten K; Holli K; Blomqvist C; Kallioniemi OP; Nevanlinna H
    Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells.
    Mohammadzadeh R; Saeid Harouyan M; Ale Taha SM
    Tumour Biol; 2017 Mar; 39(3):1010428317695925. PubMed ID: 28349828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.